GlassScriptPhysician profile
Thomas J Hope
NPI 1235223215
$3,066.69
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $482 · 2021: $1,128 · 2022: $333 · 2023: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $707.96 | 2019-2021 | |
| Abbvie INC. | $374.72 | 2019-2023 | |
| Pfizer INC. | $326.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $199.03 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $188.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $161.71 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.67 | 2019-2022 | |
| Amgen INC. | $89.88 | 2021-2022 | |
| Eisai INC. | $66.85 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $65.46 | 2020-2021 | |
| Genzyme Corporation | $65.21 | 2021 | |
| Curium US LLC | $43.32 | 2023 | |
| Sanofi-Aventis U.S. LLC | $41.79 | 2019 | |
| Lilly USA, LLC | $41.37 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.36 | 2019-2021 | |
| Novo Nordisk INC | $35.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.10 | 2021-2022 | |
| Esperion Therapeutics, INC. | $34.43 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $26.88 | 2021 | |
| Almatica Pharma LLC | $24.57 | 2021 | |
| Therapeuticsmd, INC. | $23.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.16 | 2021 | |
| Abbott Laboratories | $19.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.63 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.72 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.22 | 2021 | |
| Nevro Corp. | $15.55 | 2019 | |
| Allergan, INC. | $14.43 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.